REACT
Research type
Research Study
Full title
A double blind Randomized clinical study to Evaluate Attention improvement in a young population after CereboosT intake.
IRAS ID
355890
Contact name
David Vauzour
Contact email
Sponsor organisation
University of East Anglia
Duration of Study in the UK
1 years, 6 months, 9 days
Research summary
Lifestyle strategies such as nutritional interventions have received increased attention as they provide safe and effective solutions to improve cognitive performance. Ginseng, a popular herbal root extract obtained from plants of the Panax family is widely regarded as a remedy in traditional medicine and has been used for centuries to treat mental and physical ailments and promote longevity. Ginseng contains a number of bioactives, including flavonoids and other phenolic compounds, essential oils, and vitamins. However, the main bioactive ingredients in ginseng are purported to be ginsenosides including Rb1, Re, Rd, and F11. Among multiple species of ginseng, American ginseng (Panax quinquefolius) provides a particularly rich source of these ginsenosides when compared to other ginseng varieties, and emerging research suggests that supplementation with Panax quinquefolius may elicit cognitive enhancement effects. Cereboost® from Givaudan SA is a standardised extract of American ginseng and has been reported to exert such benefits.
We are interested in conducting a large study to further investigate the acute (0-6 hours) benefits of a single dose (200mg) of American ginseng (CereboostTM) on attention and cognitive function. The study will be conducted from the Clinical Research Facility within the Quadram Institute, an NHS facility that brings together researchers and scientists from the Norfolk and Norwich University Hospital and University of East Anglia (UEA). Researchers from the UEA will recruit 200 (i.e. n=100 control and treatment group) healthy adults (aged 18-40) to take part in the study. Participants will complete a baseline battery of cognitive tasks before being administered with either the study product or placebo. The test battery will be repeated at 2, 4 and 6 hours post administration.
REC name
South West - Central Bristol Research Ethics Committee
REC reference
25/SW/0086
Date of REC Opinion
28 Aug 2025
REC opinion
Further Information Favourable Opinion